A framework for the development of effective anti-metastatic agents

RL Anderson, T Balasas, J Callaghan… - Nature Reviews …, 2019 - nature.com
Most cancer-related deaths are a result of metastasis, and thus the importance of this
process as a target of therapy cannot be understated. By asking 'how can we effectively treat …

Mission possible: advances in MYC therapeutic targeting in cancer

BL Allen-Petersen, RC Sears - BioDrugs, 2019 - Springer
MYC is a master transcriptional regulator that controls almost all cellular processes. Over the
last several decades, researchers have strived to define the context-dependent …

First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors

SA Piha-Paul, JC Sachdev, M Barve, P LoRusso… - Clinical Cancer …, 2019 - AACR
Purpose: Bromodomain and extraterminal (BET) proteins play important roles in
transcriptional regulation relevant to cancer pathogenesis, and therapeutic …

Natural polymer-based hydrogels: From polymer to biomedical applications

L Zhao, Y Zhou, J Zhang, H Liang, X Chen, H Tan - Pharmaceutics, 2023 - mdpi.com
Hydrogels prepared from natural polymer have attracted extensive attention in biomedical
fields such as drug delivery, wound healing, and regenerative medicine due to their good …

Designing multi-targeted agents: An emerging anticancer drug discovery paradigm

R Fu, Y Sun, W Sheng, D Liao - European journal of medicinal chemistry, 2017 - Elsevier
The dominant paradigm in drug discovery is to design ligands with maximum selectivity to
act on individual drug targets. With the target-based approach, many new chemical entities …

BET bromodomain inhibitors: novel design strategies and therapeutic applications

KKW To, E Xing, RC Larue, PK Li - Molecules, 2023 - mdpi.com
The mammalian bromodomain and extra-terminal domain (BET) family of proteins consists
of four conserved members (Brd2, Brd3, Brd4, and Brdt) that regulate numerous cancer …

Emerging roles of and therapeutic strategies targeting BRD4 in cancer

ME White, JM Fenger, WE Carson III - Cellular immunology, 2019 - Elsevier
Abstract The Bromodomain and Extra-terminal (BET) family of proteins were first recognized
as important epigenetic regulators in inflammatory processes; however, there is increasing …

Targeting the tumor microenvironment in neuroblastoma: recent advances and future directions

S Joshi - Cancers, 2020 - mdpi.com
Neuroblastoma (NB) is the most common pediatric tumor malignancy that originates from the
neural crest and accounts for more than 15% of all the childhood deaths from cancer. The …

Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the …

S Joshi, DL Durden - Journal of oncology, 2019 - Wiley Online Library
Cancer immunotherapy, including immune checkpoint blockade and adoptive CAR T‐cell
therapy, has clearly established itself as an important modality to treat melanoma and other …

“Re-educating” tumor associated macrophages as a novel immunotherapy strategy for neuroblastoma

KX Liu, S Joshi - Frontiers in immunology, 2020 - frontiersin.org
Neuroblastoma is the most common extracranial pediatric tumor and often presents with
metastatic disease, and patients with high-risk neuroblastoma have survival rates of~ 50 …